Notably, the bicistronic design proved more effective for diseases co-expressing both BCMA and GPRC5D, highlighting the enhanced therapeutic efficacy of dual-targeted CAR-T cells through intensified interaction with tumor cells 10. Here, TNFRSF17 is linked to neoplasm.